VYNE Therapeutics Inc. (NASDAQ:VYNE) went down by -0.62% from its latest closing price compared to the recent 1-year high of $7.48. The company’s stock price has collected 5.92% of gains in the last five trading sessions. Press Release reported on 10/01/20 that VYNE Therapeutics Announces ZILXI(TM) (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
Is It Worth Investing in VYNE Therapeutics Inc. (NASDAQ :VYNE) Right Now?
Opinions of the stock are interesting as 7 analysts out of 7 who provided ratings for VYNE Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.00. VYNE currently public float of 138.08M and currently shorts hold a 4.88% ratio of that float. Today, the average trading volume of VYNE was 2.28M shares.
VYNE’s Market Performance
VYNE stocks went up by 5.92% for the week, with a monthly jump of 13.38% and a quarterly performance of -2.42%, while its annual performance rate touched -63.07%. The volatility ratio for the week stands at 7.20% while the volatility levels for the past 30 days are set at 10.11% for VYNE Therapeutics Inc.. The simple moving average for the period of the last 20 days is 0.94% for VYNE stocks with a simple moving average of -40.84% for the last 200 days.
VYNE Trading at 0.75% from the 50-Day Moving Average
After a stumble in the market that brought VYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.48% of loss for the given period.
Volatility was left at 10.11%, however, over the last 30 days, the volatility rate increased by 7.20%, as shares surge +16.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.59% lower at present.
During the last 5 trading sessions, VYNE rose by +5.92%, which changed the moving average for the period of 200-days by -66.87% in comparison to the 20-day moving average, which settled at $1.6065. In addition, VYNE Therapeutics Inc. saw -65.30% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for VYNE
Equity return is now at value -400.60, with -209.80 for asset returns.